Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects

被引:32
作者
Chrousos, GP [1 ]
Ghaly, L
Shedden, A
Iezzoni, DG
Harris, AG
机构
[1] Univ Athens, Sch Med, Dept Pediat 1, Aghia Sophia Childrens Hosp, GR-11527 Athens, Greece
[2] Integrated Therapeut Grp, Kenilworth, NJ USA
关键词
asthma; beclomethasone dipropionate; corticosteroid; hypothalamo-hypophyseal system; mometasone furoate;
D O I
10.1378/chest.128.1.70
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Mometasone furoate dry powder inhaler (MF-DPI) [400 mu g] is an inhaled corticosteroid (ICS) that is effective in the treatment of asthma. MF-DPl has a low potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis at its clinical dose. The effect of MF-DPI, 400 mu g qd, on the UPA axis was compared to that of beclomethasone dipropionate (BDP) using hydrofluoroalkane, (HFA) and chlorofluorocarbon (CFC) propellants via metered-dose inhalers (MDIs) twice daily. Design and interventions: This randomized, third-party blind, parallel-group study compared the effects of MF-DPl 400 mu g one puff qd in the morning (n 18), HFA-BDP 200 mu g two puffs MDI bid (n = 18), and CFC-BDP 400 mu g two puffs MDI bid (n 17) for 14 days on the area under the 24-h serum cortisol concentrations curve (AUC(0-24)) and on total 24-h urinary free cortisol excretion in mild asthmatic subjects. Effects on morning/evening peak expiratory How (PEF) and on inhaled albuterol use were also assessed. Adverse events that occurred during or >= 30 days after the study were recorded. Results: The mean decrease from baseline in the serum cortisol concentrations AUC(0-24) in the MF-DPI group was significantly less than in either the HFA-BDP (p = 0.024) or the CFC-BDP (p = 0.011) groups. Decreases in serum cortisol concentrations AUC(0-24) in the two BDP groups did not differ from one another. The MF-DPI group trended toward higher morning and evening PEF than either BDP group. Treatment-associated adverse events were reported by seven subjects in the MF-DP1 group, vs one subject in the HFA-BDP and three subjects in the CFC-BDP groups; these were mild, and no subject discontinued treatment due to an adverse event. Conclusions: Fourteen days of treatment with MF-DP1 400 mu g qd was associated with a significantly lesser decrease in the serum cortisol concentrations AUC(0-24) compared With HFA-BDP 200 mu g MDI or CFC-BDP 400 mu g MDI bid.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 23 条
[1]   Comparison of the low dose short synacthen test (1 μg), the conventional dose short synacthen test (250 μg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease [J].
Abdu, TAM ;
Elhadd, TA ;
Neary, R ;
Clayton, RN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (03) :838-843
[2]  
Affrime MB, 2000, J CLIN PHARMACOL, V40, P1227
[3]   Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses [J].
Affrime, MB ;
Kosoglou, T ;
Thonoor, CM ;
Flannery, BE ;
Herron, JM .
CHEST, 2000, 118 (06) :1538-1546
[4]   Efficacy of inhaled corticosteroids in asthma [J].
Barnes, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :531-538
[5]   Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study [J].
Brutsche, MH ;
Brutsche, IC ;
Munavvar, M ;
Langley, SJ ;
Masterson, CM ;
Daley-Yates, PT ;
Brown, R ;
Custovic, A ;
Woodcock, A .
LANCET, 2000, 356 (9229) :556-561
[6]   Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy - 1. General principles [J].
Chrousos, GP ;
Harris, AG .
NEUROIMMUNOMODULATION, 1998, 5 (06) :277-287
[7]   Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma [J].
Daley-Yates, PT ;
Tournant, J ;
Kunka, RL .
CLINICAL PHARMACOKINETICS, 2000, 39 (Suppl 1) :39-45
[8]   Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler [J].
Dempsey, OJ ;
Wilson, AM ;
Coutie, WJR ;
Lipworth, BJ .
CHEST, 1999, 116 (04) :935-940
[9]   Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: Unreliability of urinary free cortisol estimation [J].
Fink, RS ;
Pierre, LN ;
Daley-Yates, PT ;
Richards, DH ;
Gibson, A ;
Honour, JW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4541-4546
[10]   Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related duality of life in patients with severe persistent asthma [J].
Fish, JE ;
Karpel, JP ;
Craig, TJ ;
Bensch, GW ;
Noonan, M ;
Webb, DR ;
Silverman, B ;
Schenkel, EJ ;
Rooklin, AR ;
Ramsdell, JW ;
Nathan, R ;
Leflein, JG ;
Grossman, J ;
Graft, DF ;
Gower, RG ;
Garay, SM ;
Frigas, E ;
DeGraff, AC ;
Bronsky, EA ;
Bernstein, DI ;
Berger, W ;
Shneyer, L ;
Nolop, KB ;
Harrison, JE .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (05) :852-860